AKT1 and triple-negative breast carcinoma: The MEK5/ERK5 pathway has also been linked to Akt signaling,with Akt being found to phosphorylate MEKK3, the upstream kinase ofMEK5.62 Combinations of the pan-Akt ATP-siteinhibitor ipatasertib and the ERK5 inhibitors XMD8-92 and AX15836have been investigated in triple-negative breast cancer cell lines.63 In this study, ipatasertib in combination withXMD8-92 synergistically decreased TNBC cell viability while sparingMCF-10 cells.